Argent BioPharma (ASX:RGT) has marked a significant commercial step forward with the arrival of its largest-ever shipment of CannEpil in Ireland, signalling both expanding European market traction and the company’s growing operational scale.
The company said the delivery of 1,000 units represents the biggest single commercial consignment in its history and carries an estimated reimbursed retail value of about $783,000.
The shipment has been received by the company’s Irish distribution network, with Georgelle Pharma overseeing local distribution, and logistics handled in collaboration with its European partner, Versa Pharmaceuticals.
The delivery follows the first production run of CannEpil manufactured through Argent’s OEM partner under EU-GMP standards.
CannEpil is Argent BioPharma’s pharmaceutical-grade cannabinoid formulation developed for neurological conditions, particularly for managing seizures linked to refractory epilepsy. This condition remains a major global treatment challenge, affecting roughly 30 per cent of epilepsy patients who fail to achieve adequate seizure control using conventional therapies. Such patients often experience persistent seizures, diminished quality of life, and increased interaction with healthcare systems.
The product incorporates defined cannabinoid ratios and strict pharmaceutical quality controls to ensure consistency, safety, and precise dosing. CannEpil has undergone clinical evaluation and is already supplied through regulated prescribing frameworks in several jurisdictions. In Ireland, the treatment is available through approved medical channels and is fully reimbursed under the national health insurance system, allowing eligible patients to access the therapy under physician supervision.
At a reimbursement price of €467 per unit, the shipment’s total retail value approaches A$783,000, though the company notes that final revenues will depend on the number of units ultimately dispensed and the pricing mechanics across the Irish healthcare distribution chain.
According to Managing Director and CEO Roby Zomer, the milestone demonstrates the company’s ability to align manufacturing execution, regulatory access, and clinical positioning. He described the shipment as an important inflection point that validates the firm’s European supply chain and supports the next phase of its growth strategy.
The development also reinforces CannEpil’s role within Argent’s broader neurological portfolio. As a clinical-stage biopharmaceutical company, Argent is focused on advancing nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its pipeline includes CannEpil for drug-resistant epilepsy and CimetrA for inflammatory conditions, both supported by proprietary nano-delivery technologies intended to improve bioavailability and tissue penetration.